metaPreg - Leflunomide during pregnancy

Leflunomide updated on 06-01-2019

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	0.97 [0.81, 1.16]	0%	3 studies	14,378	116	not evaluable	ROB	-
Major congenital malformations	0.97 [0.81, 1.16]	0%	3 studies	14,378	116	not evaluable	ROB	-
4 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.04 [1.07, 3.90]	0%	2 studies	10,868	77	not evaluable	ROB	3.50 [1.33; .]
Low birth weight (< 2500g)	1.06 [0.90, 1.25]	0%	2 studies	2	3	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	-	-	0 study					-
2 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions	1.09 [0.90, 1.32]	0%	2 studies	17,747	112	not evaluable	ROB	-
3 non statistically significant endpoints reported in only one study
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value